ABOUT
Insight - Innovation - Access - Engagement - Partnering
The one summit which convenes a high level, by-invitation, boutique gathering of key thought leaders, innovators and decision-makers from all key stakeholder groups in digital health, tech and A.I. for neurosciences and mental health. Addressing not only opportunities but also the core challenges facing companies and stakeholders. Sharing models, lessons learned, mistakes, solutions, ways forward and best practices. Fostering a unique level of sustained high-quality discussion, access, engagement and partnering in a truly curated summit unlike any other event.
VISION
Convening the full value chain to disrupt silos and curate highly interactive, multi-disciplinary, cross-industry, and multi-stakeholder discussions of opportunities, challenges, hurdles and ways forward.
Drive transformational connections, discussion and partnering for startups and growth companies.
Deliver insight, access, engagement and partnering to foster innovation and accelerate value creation.
Contribute to meaningful improvement in healthcare outcomes and positive impact for patients and society.
WHY NOW?
From A.I. enabled drug discovery and development, big data, digital biomarkers, Real World Data and trial design, to advanced imaging, companion digital health, cognitive behavioral therapy and connected health, to neuromodulation and V.R., the pace of innovation is unprecedented.
Paradigms are changing, and the potential for positive impact on patient outcomes and quality of life, improved delivery of care, healthcare expenditure, and societal benefit are enormous.
The Neuro, Digital & A.I. Innovation Summit is organized by Broadreach Global and Hosted by the Champalimaud Foundation, with Partners the European Brain Council (EBC), and the support of our Global Innovation Partners and other key stakeholder organizations.
The launch edition in 2022 delivered a unique, meaningful and high-impact initiative unlike other events. Join us in 2023.
PRESENTING COMPANIES
Join a curated selection of the best, world-class , innovative neuro and mental health companies in Digital, MedTech, DeepTech, Data & A.I. with potential to transform healthcare, patient outcomes or markets. Selection is by excellence and potential, not by price tag!
There is no cost to present beyond the regular startup or private company registration fees.
Benefit from:
- Pre-summit guidance and feedback on your deck.
- An on-site dry-run presentation with feedback and coaching from expert mentors.
- A3 minute pitch plus 3 minutes of Q&A with an expert panel of relevant investors, industry & experts.
- 2.5 Days of sustained engagement with the best network of innovators, investors, industry leaders & decision-makers in brain health digital, medtech, deeptech & A.I.
ADVISORY BOARD
We are honored to introduce our advisory board: meet them in person at the summit.
 Joe PatonDirector of Neuroscience & Principal Investigator, Champalimaud Foundation |  Ana MaiquesCEO & Co-Founder, Neuroelectrics |  Paulo MachadoCEO/Founder - Health Innovation Partners, Angel - What if Ventures, Strategic Advisor - Meadows Mental Health Policy Institute |  Pawel SwiebodaFounder - NeuroCentury; Practice Lead Neurotechnology, ICFG; Senior Advisor on Brain Health, FIPRA |
|---|---|---|---|
 Shwen GweeDigital Health & Corporate Innovation Executive, ex BMS Global Head of Digital Strategy, ex-Novartis BIOME & Open Innovation co-founder |  Mark TreherneChairperson - Monument Therapeutics. Commercial Scientist, Entrepreneur & Investor. Chairperson of Talisman Therapeutics, Ubiqent, NuVision Biotherapies |  Joachim ScholppGlobal Head Translational Medicine CNS & Emerging Areas, Boehringer Ingelheim, Germany |  Naomi GloverCo-Founder/Director, Applied Neuroscience Association |
 Christian J. SuojanenFounder & CEO - Broadreach Global, Member of the Board - European Brain Foundation (EBF) |  Fred DestrebecqExecutive Director, European Brain Council (EBC) |
SPEAKERS
Proudly convening leading speakers and stakeholders from across the sector
 John KrakauerProfessor of Neurology, Neuroscience, and Physical Medicine & Rehabilitation - Johns Hopkins School of Medicine (Maryland) | Ana MaiquesCEO & Co-Founder - Neuroelectrics (Barcelona) |  Zenna TavaresFounder & Director - Basis Research Institute, Research Scientist - Data Science Institute & Innovation Fellow - Zuckerman Mind Brain Behavior Institute - Columbia University, New York |  Daniela Pimenta da SilvaNeurologist and PhD student - CNS-Campus Neurologico and Faculty of Medicine of the University of Lisbon |
|---|---|---|---|
 Daniel WetmoreSenior Research Scientist – Meta Reality Labs, NY, NY | Joe PatonDirector of Neuroscience & Principal Investigator, Champalimaud Foundation | Joachim ScholppGlobal Head Translational Medicine CNS & Emerging Areas, Boehringer Ingelheim, Germany |  Nick TaptiklisHead of Technology Strategy - Cambridge Cognition (UK) |
 Georgia MitsiEnterpreneur in Residence - Emerald BioVentures (Boston) | Pawel SwiebodaFounder - NeuroCentury; Practice Lead Neurotechnology, ICFG; Senior Advisor on Brain Health, FIPRA |  Ariane Tom, PhDFounding Partner - Kaleida Capital (San Diego) |  David Braga MaltaLife Sciences Investor & Entrepreneur - PE Thematic Health, Pictet Bank (Switzerland) |
 Gilad PelegFounding Partner - LifeOne Ventures (Israel) | Paulo MachadoCEO/Founder - Health Innovation Partners, Angel - What if Ventures, Strategic Advisor - Meadows Mental Health Policy Institute |  Amir BozorgzadehCo-Founder & CEO - Virtuleap |  Bruno MontanariPartner - Seroba Life Sciences, Paris |
 Beth WolfDirector Digital Health Solutions, Global Corporate Strategy & BD - Lundbeck, Copenhagen | Mark TreherneChairperson - Monument Therapeutics. Commercial Scientist, Entrepreneur & Investor. Chairperson of Talisman Therapeutics, Ubiqent, NuVision Biotherapies (UK) |  Julia PrakapovichPartner - Interface Fund (London) |  Dan MannixCEO - Advisor - Brain Health Investor, former CEO - RWC Partners (UK) |
 Tiago MarquesSenior Research Scientist - Champalimaud Foundation, Chief Technology Office - HEKA vision, Lisbon |  Razi SyedHead of Product - Sahha |  Xavier LouisCo-founder & CEO - Five Lives |  Carla Zaldua Aguirre,Co-Founder & CEO - acceXible |
 Olivier de SimoneCo-Founder & CEO - Sensae |  Dr. Laura MurrayClinical Psychologist, CEO/Founder - CETA Global; Senior Scientist - Johns Hopkins Bloomberg School of Public Health, Entrepreneur, Researcher and Clinician (Maryland) |  Joshua HaynesFounder & Managing Partner - Masawa Fund (Berlin) | Shwen GweeDigital Health & Corporate Innovation Executive, ex BMS Global Head of Digital Strategy, ex-Novartis BIOME & Open Innovation co-founder (Boston) |
 Hossein JalaliCofounder & CTO - Virtuleap | Naomi GloverCo-Founder/Director - Applied Neuroscience Association (London) |  Hannes KlöpperCEO - HelloBetter Co-Chair - European Policy Task Group of the Digital Therapeutics Alliance |  Marco MohwinckelMental Health Executive & Investor, Chairman – Altibbi, Director - Magnolia Health Advisors (London) |
 Xavier Palomer RipollFounder - Amelia Virtual Care |  Amanda BorgerhoffVice President Client Services - Warman O'Brien |  JP BorgesManaging Partner - JP Borges Abogados, Co-Founder - Exputnik Accelerator (Spain) |  Mick WalshVP Commercial & Business Development - Head Diagnostics (Ireland) |
 Hana BesbesInvestor - Heal Capital (Berlin) |  Jason DictenbergInvestor, Executive, CEO - AccelBio, Chairman - Evergreen Biosciences, Advisory Board Member - Alzheimer's Drug Discovery Foundation, Editor - CellR4 Journal on Regenerative Medicine (New York) |  Richard StokvisManaging Director - BOA Healthcare Holdings Limited |  Lorena Muñoz VivasCEO - Effectia Consulting (Spain) |
 Christian J. SuojanenCEO - Broadreach Global, Member of the Executive Board - European Brain Foundation (USA) |
PRESENTING COMPANIES
.png){kind=small}
WHO'S COMING?
Two days of sustained, interactive discussion, networking and partnering with:
Industry Leaders
Senior industry executives from pharma, digital health, technology & health providers & systems. Heads of therapeutic area, R&D, real world data, clinical development, digital health, scouting, business development & licensing.
Key Opinion Leaders
Key Opinion Leaders from all stakeholder groups at the confluence of neurosciences & mental health with digital, technology, data and A.I.
Founders & CEOs
From startup and growth companies at the confluence of neuroscience and mental health with digital, medtech, imaging, technology, data and A.I.
Government & NGOs
Public agencies, societies, associations & NGOs in brain health, neurology, neurosciences, psychiatry & mental health, patient organizations, economic development, health, research & innovation.
Investors
In CNS, neuroscience and mental health, data, health tech, digital health, A.I. and deeptech.
VC and corporate venture, private equity, family offices, angels & HNW.
Leading Advisors
A selected group of leading specialized advisors and consultants with deep subject matter expertise relevant to participants.
SCHEDULE
The full agenda and program will be shared soon. In the meantime, here are some general timings, to help you plan your time in Lisbon. These are for reference only and subject to change as additional sessions and activities are added and final program updates are made.
As always, at The Neuro Summit, all speakers, presenters and participants are encouraged to actively engage and participate throughout, not just in their own sessions.
Oct. 11
14:00 - Registration, Coffee & Networking Open
15:30 - Initial Welcome, Opening Keynote & Panel session
17:30 - End of pre-program - Welcome Networking to 19:15
Oct. 12
08:30 - Registration, Coffee & Networking Open
09:00 - Official Inauguration and Welcome
12:30 - Networking Lunch
17:45 - End of Day II - Networking Reception to 20:00
Oct. 13
08:30 - Registration, Coffee & Networking Open
09:00 - Program Starts
12:45 - End of Summit Program
VENUE
Champalimaud Foundation
Av. Brasília, 1400-038
Lisbon, Portugal
The Champalimaud Foundation carries out research in cutting-edge fields and strives to stimulate discoveries that benefit people, and to promote new standards of knowledge.
It is at the Champalimaud Centre for the Unknown, in Lisbon, that the Foundation develops its activity in the areas of neuroscience and cancer. This is done through both research programmes and the provision of clinical services of excellence. It also has an outreach programme to fight blindness.
To pursue its objectives in achieving significant scientific advances, the Champalimaud Foundation adopts a translational methodology, which establishes a direct link and interdependency between basic research and clinical activity. This is a fundamental part of the Foundation’s methodology.
Ultimately, the Champalimaud Foundation aims to promote the health and well-being of humankind by seeking to actively participate in the search for solutions that can alleviate the burden of disease on societies and individuals.
CO-ORGANIZED WITH
ASSOCIATION PARTNER
HOST PARTNER
STRATEGIC PARTNERS & SPONSORS
PLATINUM SPONSOR
GOLD SPONSOR
STRATEGIC PARTNERS
ASSOCIATION PARTNERS
GET IN TOUCH
Reach us here if you like to
-
Nominate a speaker
-
Apply to present your company or technology
-
Enquire about sponsorship & exhibition opportunities
Be the first to know
Subscribe and be among the first to receive all updates, announcements and invitations.
Please make sure to double check your email address.
SHARE
A Broadreach Global Initiative
Contact us at:
Follow us
